Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: WAC

Gene summary for WAC

Gene summary.

Gene information	Species	Human
	Gene symbol	WAC
	Gene ID	51322
	Gene name	WW domain containing adaptor with coiled-coil
	Gene Alias	BM-016
	Cytomap	10p12.1
	Gene Type	protein-coding
	GO ID	GO:0000075
	UniProtAcc	Q9BTA9

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
51322	WAC	CA_HPV_1	Human	Cervix	CC	1.14e-06	-6.65e-02	0.0264
51322	WAC	CCI_1	Human	Cervix	CC	1.16e-04	8.37e-01	0.528
51322	WAC	CCI_2	Human	Cervix	CC	1.16e-07	1.19e+00	0.5249
51322	WAC	CCI_3	Human	Cervix	CC	1.36e-08	8.37e-01	0.516
51322	WAC	L1	Human	Cervix	CC	2.71e-03	-2.29e-01	0.0802
51322	WAC	HTA11_3410_2000001011	Human	Colorectum	AD	1.13e-21	-6.27e-01	0.0155
51322	WAC	HTA11_1938_2000001011	Human	Colorectum	AD	6.84e-04	4.80e-01	-0.0811
51322	WAC	HTA11_347_2000001011	Human	Colorectum	AD	4.17e-05	3.81e-01	-0.1954
51322	WAC	HTA11_99999965062_69753	Human	Colorectum	MSI-H	2.63e-04	8.29e-01	0.3487
51322	WAC	HTA11_99999965104_69814	Human	Colorectum	MSS	5.25e-08	5.98e-01	0.281
51322	WAC	HTA11_99999974143_84620	Human	Colorectum	MSS	6.48e-06	-4.08e-01	0.3005
51322	WAC	A001-C-207	Human	Colorectum	FAP	2.54e-04	-1.50e-01	0.1278
51322	WAC	A015-C-203	Human	Colorectum	FAP	4.61e-34	-3.28e-01	-0.1294
51322	WAC	A015-C-204	Human	Colorectum	FAP	1.28e-07	-2.69e-01	-0.0228
51322	WAC	A014-C-040	Human	Colorectum	FAP	1.45e-06	-3.98e-01	-0.1184
51322	WAC	A002-C-201	Human	Colorectum	FAP	4.30e-14	-2.96e-01	0.0324
51322	WAC	A002-C-203	Human	Colorectum	FAP	1.22e-03	-1.48e-01	0.2786
51322	WAC	A001-C-119	Human	Colorectum	FAP	2.35e-05	-2.70e-01	-0.1557
51322	WAC	A001-C-108	Human	Colorectum	FAP	7.60e-15	-2.23e-01	-0.0272
51322	WAC	A002-C-205	Human	Colorectum	FAP	1.13e-27	-3.87e-01	-0.1236

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00103902	Oral cavity	NEOLP	histone monoubiquitination	9/2005	29/18723	2.48e-03	1.57e-02	9
GO:190305132	Oral cavity	NEOLP	negative regulation of proteolysis involved in cellular protein catabolic process	15/2005	64/18723	2.63e-03	1.65e-02	15
GO:004277031	Oral cavity	NEOLP	signal transduction in response to DNA damage	30/2005	172/18723	4.92e-03	2.67e-02	30
GO:190336332	Oral cavity	NEOLP	negative regulation of cellular protein catabolic process	16/2005	75/18723	5.24e-03	2.81e-02	16
GO:00335232	Oral cavity	NEOLP	histone H2B ubiquitination	5/2005	12/18723	5.81e-03	3.04e-02	5
GO:200004531	Oral cavity	NEOLP	regulation of G1/S transition of mitotic cell cycle	25/2005	142/18723	8.58e-03	4.15e-02	25
GO:003243522	Oral cavity	NEOLP	negative regulation of proteasomal ubiquitin-dependent protein catabolic process	9/2005	35/18723	9.72e-03	4.55e-02	9
GO:004217618	Prostate	BPH	regulation of protein catabolic process	139/3107	391/18723	3.71e-20	3.28e-17	139
GO:000989618	Prostate	BPH	positive regulation of catabolic process	156/3107	492/18723	4.50e-17	1.11e-14	156
GO:001049818	Prostate	BPH	proteasomal protein catabolic process	153/3107	490/18723	4.13e-16	7.51e-14	153
GO:003133118	Prostate	BPH	positive regulation of cellular catabolic process	135/3107	427/18723	7.82e-15	1.05e-12	135
GO:190336218	Prostate	BPH	regulation of cellular protein catabolic process	93/3107	255/18723	1.06e-14	1.40e-12	93
GO:004316118	Prostate	BPH	proteasome-mediated ubiquitin-dependent protein catabolic process	127/3107	412/18723	3.84e-13	3.60e-11	127
GO:200005818	Prostate	BPH	regulation of ubiquitin-dependent protein catabolic process	66/3107	164/18723	4.20e-13	3.88e-11	66
GO:190305018	Prostate	BPH	regulation of proteolysis involved in cellular protein catabolic process	80/3107	221/18723	1.20e-12	1.02e-10	80
GO:003243418	Prostate	BPH	regulation of proteasomal ubiquitin-dependent protein catabolic process	54/3107	134/18723	5.22e-11	3.29e-09	54
GO:006113618	Prostate	BPH	regulation of proteasomal protein catabolic process	67/3107	187/18723	1.34e-10	7.74e-09	67
GO:000989517	Prostate	BPH	negative regulation of catabolic process	94/3107	320/18723	6.79e-09	2.38e-07	94
GO:004217717	Prostate	BPH	negative regulation of protein catabolic process	46/3107	121/18723	1.22e-08	3.99e-07	46
GO:003133018	Prostate	BPH	negative regulation of cellular catabolic process	79/3107	262/18723	3.09e-08	8.91e-07	79

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

WAC

SNV

Missense_Mutation

c.306C>G

p.His102Gln

p.H102Q

Q9BTA9

protein_coding

tolerated(0.13)

benign(0.063)

TCGA-A2-A3XT-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

WAC

SNV

Missense_Mutation

c.1142N>C

p.Val381Ala

p.V381A

Q9BTA9

protein_coding

deleterious(0.03)

possibly_damaging(0.503)

TCGA-A8-A06X-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WAC

SNV

Missense_Mutation

novel

c.1798N>A

p.Glu600Lys

p.E600K

Q9BTA9

protein_coding

tolerated(0.09)

probably_damaging(0.972)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WAC

SNV

Missense_Mutation

novel

c.16A>G

p.Arg6Gly

p.R6G

Q9BTA9

protein_coding

deleterious(0.04)

benign(0)

TCGA-AQ-A7U7-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Targeted Molecular therapy

rituximab

WAC

SNV

Missense_Mutation

rs200723559

c.1586N>G

p.Asn529Ser

p.N529S

Q9BTA9

protein_coding

tolerated(0.13)

possibly_damaging(0.584)

TCGA-BH-A0E0-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

docetaxel

WAC

SNV

Missense_Mutation

rs750794271

c.376N>C

p.Asp126His

p.D126H

Q9BTA9

protein_coding

deleterious(0.01)

probably_damaging(0.995)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

WAC

SNV

Missense_Mutation

c.1887N>C

p.Leu629Phe

p.L629F

Q9BTA9

protein_coding

deleterious(0)

probably_damaging(0.991)

TCGA-E2-A10C-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

WAC

SNV

Missense_Mutation

c.1595C>A

p.Ser532Tyr

p.S532Y

Q9BTA9

protein_coding

tolerated(1)

possibly_damaging(0.598)

TCGA-GM-A2D9-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

WAC

insertion

Frame_Shift_Ins

novel

c.1537_1538insT

p.Arg513LeufsTer8

p.R513Lfs*8

Q9BTA9

protein_coding

TCGA-A2-A0EO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

WAC

insertion

Frame_Shift_Ins

novel

c.1538_1539insAGGGAGAATTATTAATCATATCCCCTCACCCCACCAA

p.Ser514GlyfsTer19

p.S514Gfs*19

Q9BTA9

protein_coding

TCGA-A2-A0EO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

Page: 1 2 3 4 5 6 7 8

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1